Shots:

• The companies collaborated to evaluate OncoSec's TAVO + Merck's Keytruda vs SoC in a P-III KEYNOTE-C87 trial in ~400 patients with metastatic melanoma who are refractory to immune checkpoint therapy across the US- Canada- EU & Australia
• The companies will responsible for internal costs with OncoSec covering the third-party costs. The trial is intended to support accelerated approval or a full licensure of the combination in the US
• TAVO demonstrated a local & systemic anti-tumor response in several clinical trials- including the P-IIb KEYNOTE-695 trial for metastatic melanoma & P-II KEYNOTE-890 trial for TNBC

  Ref: PR Newswire | Image: Merck